A phase III study of neoadjuvant bicalutamide in patients with intermediate risk prostate cancer undergoing radiation therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN64733264

Enrollment

360

Registered

2005-01-25

Start date

1999-07-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Localised prostate cancer Cancer Prostate cancer

Interventions

Bicalutamide 150 mg daily for 3 months before and 2 months during radiation therapy versus no hormonal therapy.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. T1/T2a prostate cancer with: 1.1. Gleason 7, prostate specific antigen (PSA) less than 20 ng/ml 1.2. Gleason less than 7, PSA 10 - 20 ng/ml 2. T2b prostate cancer with: 2.1. PSA less than 20 ng/ml 2.2. Gleason less than or equal to 7

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026